Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast Cancer
Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Ecaterina Ileana Dumbrava, MD, an assistant professor in the Department of Investigational Cancer Therapeutics, of the Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
BDC-1001 is currently being studied in an ongoing phase 1 study to determine, safety, durability and proper dosage. According to Dumbrava, synergistic activity was seen between the 2 agents in preclinical models. These preclinical model also had anti-PB1 activity and immunologic memory.
It was hypothesized that the activity observed preclinically may translate in human subjects. Researchers hope that the combination will lead to a durable and sustained responses.
T-DXd Shows Effectiveness in Treating HER2+ Advanced Solid Tumors
April 1st 2024The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.
Read More
Challenges Persist for HCPs and Patients With Breast Cancer
March 1st 2024In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.
Read More
